Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Biomarker returned 72 record(s)
|
|
Sunday, 07/29/2018
|
An Innovative Approach to Identify Biomarker Signatures for Cancer Genetic Data with Survival Endpoints
Ming Wang, Pennsylvania State University; Zheng Li, Penn State Unviersity
|
Strategies for Validating Biomarkers Using Data from a Reference Set
Lu Wang, Fred Hutchinson Cancer Research Center; Ying Huang, Fred Hutchinson Cancer Research Center
2:20 PM
|
An Innovative Approach to Identify Biomarker Signatures for Cancer Genetic Data with Survival Endpoints
Ming Wang, Pennsylvania State University; Zheng Li, Penn State Unviersity
2:50 PM
|
Estimating Heterogeneous Biomarker Networks and Their Effects on Disease Outcome
Shanghong Xie, Columbia University; Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Donglin Zeng, UNC Chapel Hill; Yuanjia Wang, Columbia University
4:05 PM
|
Two-Stage Enrichment Clinical Trial Design with Adjustment for Misclassification in Predictive Biomarkers
Yong Lin, Rutgers, The State University of New Jersey; Weichung Joe Shih, Rutgers University; Shou-En Lu, Rutgers University
4:35 PM
|
Spatial Statistics Approach to Develop Novel Protein Cancer Biomarkers
Inna Chervoneva, Thomas Jefferson University
4:50 PM
|
|
Monday, 07/30/2018
|
Statistical Challenges in Developing Data-Driven Discovery, Diagnosis, and Treatment of Psychiatric Diseases
Thaddeus Tarpey, Wright State University
|
Comparisons of Modeling Methods on Longitudinal and Survival Data: Identifying Use of Repeat Biomarker Measurements to Predict Time-To-Event Outcome in Cancer Research
Meng Ru, Icahn School of Medicine at Mount Sinai; Erin Moshier, Icahn School of Medicine at Mount Sinai; Madhu Mazumdar, Icahn School of Medicine at Mount Sinai
|
Missing Data Framework for Estimating Biomarker Clinical Utility Under Incomplete Follow-Up
Julie Kobie, Merck Research Laboratories; Lingkang Huang, Merck Research Laboratories; Robin Mogg, Merck Research Laboratories; Jared Lunceford, Merck Research Laboratories
8:50 AM
|
Leveraging Omics Biomarker in Early Clinical Trials - Concept, Utility and Impact on Decision Making
Weidong Zhang, Pfizer Inc.
10:35 AM
|
Design and Analysis Considerations for Studies Involving Pooled Biomarker Data
Abigail Sloan, Harvard T.H. Chan School of Public Health; Molin Wang, Harvard T.H. Chan School of Public Health; Mitchell H. Gail, Division of Cancer Epidemiology and Genetics, NCI, NIH
10:50 AM
|
Inference on Treatment Effect Modification by Marker Response in a Baseline Surrogate Measure Three-Phase Sampling Design
Michal Juraska, Fred Hutchinson Cancer Research Center; Ying Huang, Fred Hutchinson Cancer Research Center; Peter Gilbert, Fred Hutchinson Cancer Research Center
10:50 AM
|
Comparisons of Modeling Methods on Longitudinal and Survival Data: Identifying Use of Repeat Biomarker Measurements to Predict Time-To-Event Outcome in Cancer Research
Meng Ru, Icahn School of Medicine at Mount Sinai; Erin Moshier, Icahn School of Medicine at Mount Sinai; Madhu Mazumdar, Icahn School of Medicine at Mount Sinai
11:15 AM
|
Statistical Methods for Pooling Categorical Biomarkers from Multiple Studies
Xiao Wu, Harvard University; Molin Wang, Harvard T.H. Chan School of Public Health
11:20 AM
|
Dealing with Methodological Issues in the Functional Data Analysis of Actigraphy Data
Stephen W. Looney, Augusta University; William Vaughn McCall, Augusta University; Jordan S. Lundeen, BlueChoice HealthPlan of South Carolina
11:35 AM
|
Developing Biomarker Combinations in Multicenter Studies via Direct Maximization and Penalization
Allison Meisner, Johns Hopkins University; Kathleen F. Kerr, University of Washington; Chirag Parikh, Yale University
11:35 AM
|
Identifying Biomarkers in Heterogeneous Samples Without Known Reference Cell Type Profiles
Kelly Mosesso, Harvard University ; Martin Aryee, Harvard University
11:35 AM
|
Maximum Diversity Weighting for Biomarkers with Application in HIV-1 Vaccine Studies
Zonglin He, Fred Hutchinson Cancer Research Center; Youyi Fong, Fred Hutchinson Cancer Research Center
11:55 AM
|
Bessel Functions and the Ordering of Changes in Biomarkers, with Application to the Hypothesized Biomarker Model in Preclinical Alzheimer Disease
Chengjie Xiong, Washington University in St Louis; Jingqin Luo, Washington University; John Morris, Washington University
12:05 PM
|
Determine Appropriate Sample Size for a Biomarker Signature Discovery Problem Using Penalized Regression
Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Hong Tian, Janssen Pharmaceutical; Liang Xiu, Janssen Research & Development, LLC
2:20 PM
|
A Generalized Design for a Confirmatory Basket Trial
Robert Beckman, Georgetown University; Xiaoyun (Nicole) Li, Merck
2:25 PM
|
Statistical Considerations for Using Multiple Databases to Build a Biomarker Probability Tool
Feng Gao; Shijia Bian, Biogen; Wenting Wang, Biogen; Nancy Maserejian, Biogen; Judith Jaeger, Albert Einstein College of Medicine; Robert Robert Engle , Biogen; Timothy Swan, Biogen; James McIninch, Alnylam Pharmaceuticals; Feng Gao, Biogen
2:25 PM
|
Bayesian Latent Hierarchical Model for Transcriptomic Meta-Analysis to Detect Biomarkers with Clustered Meta-Patterns of Differential Expression Signals
Zhiguang Huo, University of Florida; Chi Song, Ohio State University; George Tseng, University of Pittsburgh
3:05 PM
|
A Parametric Multiple Comparison Procedure for Clinical Trials with Planned Evaluation of Treatment Effect in Pre-Defined Subgroups and Interim Analyzes
Liang Fang, MyoKardia; Ron Yu, Gilead Sciences, Inc.; Zhishen Ye, Gilead Sciences; Neby Bekele, Gilead Sciences; Ming Lin, Gilead Sciences
3:05 PM
|
Powering Biomarker Discovery Studies for Training and Validation
Olga Demler, Harvard Medical School; Nancy R Cook, Harvard Medical School
3:35 PM
|
|
Tuesday, 07/31/2018
|
Analysis Framework in Integrating Data of Different Modalities with Application in Identifying Important Predictors/Subgroups in Non-Alcoholic Steatohepatitis
Tuan Nguyen, Gilead Sciences; Guang Chen, Gilead Sciences; Adarsh Joshi, Gilead Sciences, Inc.; Lulu Wang, Gilead Sciences; Yafeng Zhang, Gilead Sciences; Yuanyuan Xiao, Gilead Sciences; Catherine Jia, Gilead Sciences; Ren Xu, Gilead Sciences; Stephen Djedjos, Gilead Sciences; Rob Myers, Gilead Sciences
|
Determination of Optimal Cut-Off Points for Biomarkers in Oncology Research
Shu-Pang Huang, Bristol-Myers Squibb Co.; Tian Chen, Bristol-Myers Squibb Co.; Ye Feng, Bristol-Myers Squibb Co.; Ming Zhou, Bristol-Myers Squibb Company; Ramachandran Suresh, Bristol-Myers Squibb Co.
|
Variable Selection May Be Overrated
Tristan Grogan, UCLA; David Elashoff, UCLA
|
Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials
Danni Yu, Eli Lilly and Company
|
A Two-Stage Method to Analyze Multivariate Cluster Biomarkers in Prediction on a Single Binary Outcome
Xiaoying Yu, University of Texas Medical Branch at Galveston; Wenyaw Chan, University of Texas Health Science Center at Houston; Gracie Vargas, University of Texas Medical Branch at Galveston; Rahul Pal, University of Texas Medical Branch at Galveston
|
Integrative Statistical Analysis Pipeline for RNA-Seq and NanoString with Application to Gene Expression Data of Cancer Patients
Jeea Choi, Novartis Pharmaceuticals; Catarina D. Campbell, Novartis Institutes for BioMedical Research; Xiaoshan Wang, Novartis Pharmaceuticals; He Wei, Novartis Pharmaceuticals; Robinson Douglas, Novartis Pharmaceuticals; Stephane Wong, Novartis Pharmaceuticals; Bin Fu, Novartis Pharmaceuticals; Rebecca Leary, Novartis Institutes for BioMedical Research; Kavitha Venkatesan, Novartis Institutes for BioMedical Research; Ying A Wang, Novartis Pharmaceuticals
|
Determine Appropriate Sample Size for a Biomarker Signature Discovery Problem Using Penalized Regression
Xiang Li, Statistics and Decision Sciences, Janssen Research & Development, LLC; Hong Tian, Janssen Pharmaceutical; Liang Xiu, Janssen Research & Development, LLC
|
Statistical Considerations for Using Multiple Databases to Build a Biomarker Probability Tool
Feng Gao; Shijia Bian, Biogen; Wenting Wang, Biogen; Nancy Maserejian, Biogen; Judith Jaeger, Albert Einstein College of Medicine; Robert Robert Engle , Biogen; Timothy Swan, Biogen; James McIninch, Alnylam Pharmaceuticals; Feng Gao, Biogen
|
Issues Regarding Biomarker Combination Within ROC Framework: Strategies, Target Functions, and Large Number of Weak Markers
Lili Tian, SUNY at Buffalo; Li Yan, Roswell Park Cancer Institute; Jingjing Yin, Georgia Southern University; Le Kang, Virginia Commonwealth University
8:35 AM
|
Data-Driven Biomarker Evaluation in Adaptive Designs Using SIDES
Ilya Lipkovich, IQVIA; Alex Dmitrienko, Mediana Inc
8:35 AM
|
Integrative Statistical Analysis Pipeline for RNA-Seq and NanoString with Application to Gene Expression Data of Cancer Patients
Jeea Choi, Novartis Pharmaceuticals; Catarina D. Campbell, Novartis Institutes for BioMedical Research; Xiaoshan Wang, Novartis Pharmaceuticals; He Wei, Novartis Pharmaceuticals; Robinson Douglas, Novartis Pharmaceuticals; Stephane Wong, Novartis Pharmaceuticals; Bin Fu, Novartis Pharmaceuticals; Rebecca Leary, Novartis Institutes for BioMedical Research; Kavitha Venkatesan, Novartis Institutes for BioMedical Research; Ying A Wang, Novartis Pharmaceuticals
8:40 AM
|
Robust Combination of Biomarkers for Classification with Covariate Adjustment
Ying Huang, Fred Hutchinson Cancer Research Center; Soyoung Kim, Medical College of Wisconsin
8:55 AM
|
Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials
Danni Yu, Eli Lilly and Company
9:10 AM
|
WITHDRAWN: Combining Biomarkers to Improve Classification Accuracy Under Heterogeneous Transformations
Aiyi Liu, BBB/DIPHR/NICHD; Wei Zhang, BBB/DIPHR/NICHD
9:15 AM
|
Improved Selection of High-Dimensional Neuroimaging Biomarkers Associated with Neurodegenerative Disease Progression
Tanya Garcia, Texas A&M University; Jeffrey S Morris, The University of Texas M.D. Anderson Cancer Center
9:15 AM
|
New Dimension Reduction Methods for Combining Longitudinally Measured Biomarkers
Ruth Pfeiffer , National Cancer Institute; Wei Wang , George Washington University ; Efstathia Bura , Vienna University of Technology
9:35 AM
|
A Multi-Step Classifier Addressing Cohort Heterogeneity Improves Performance of Prognostic Biomarkers in Three Cancer Types
Ellis Patrick, University of Sydney; Samuel Mueller, The University of Sydney; Jean Yee Hwa Yang, University of Sydney, Australia
9:35 AM
|
Assessment of Biomarkers and Surrogate Endpoints in Drug Development
Ivan Chan, AbbVie Inc; Shu-Chih Su, Merck Research Labs
10:55 AM
|
A Two-Stage Method to Analyze Multivariate Cluster Biomarkers in Prediction on a Single Binary Outcome
Xiaoying Yu, University of Texas Medical Branch at Galveston; Wenyaw Chan, University of Texas Health Science Center at Houston; Gracie Vargas, University of Texas Medical Branch at Galveston; Rahul Pal, University of Texas Medical Branch at Galveston
11:10 AM
|
Limitations of Progression Free Survival as a Surrogate Marker for Overall Survival in Oncology Trials
Robin Mogg, Merck Research Laboratories; Yiwei Zhang, Merck Research Laboratories
11:15 AM
|
Developing Genomic Biomarker to Guide Personalized Patient Management in Oncology: Validity and Utility of Clinical Diagnostic Applications
Michael Crager, Genomic Health; Ruixiao Lu, Genomic Health, Inc.
11:25 AM
|
DREAM Challenges: a Community Framework for Benchmarking Reproducible Biomedical Models
Justin Guinney, Sage Bionetworks
11:35 AM
|
Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial
Rui Tang, Shire; Xiaoye Ma, University of Minnesota; Hui Yang, Amgen Inc.
11:50 AM
|
Estimating Directed Acyclic Graphs from High-Dimensional Data and Its Application in Biomarker Discoveries in Early Clinical Trials
Hua Zhong, New York University; Jaehong Yu, NYU School of Medicine
11:55 AM
|
A Bayesian Framework for Calculating Predictive Probability of Success in Biomarker Development
Cong Li; Ling Wang, Takeda; Ray Liu, Takeda Pharmaceuticals Inc
2:05 PM
|
Estimating the Receiver Operating Characteristic Curve from Clustered Data and Case-Control Studies
Yalda Zarnegarnia, University of Miami; Shari Messinger, University of Miami
2:20 PM
|
Analysis of Stratified Clinical Trials with Time-To-Event Endpoints
Devan V Mehrotra, Merck & Co., Inc.; Shanjun Helian, Merck & Co., Inc.; Shu-Chih Su, Merck Research Labs
3:05 PM
|
Reproducibility of FDG-PET Standardized Uptake Value (SUV) for Use as an Integral Biomarker in Clinical Trials
Brenda Kurland, University of Pittsburgh
3:05 PM
|
Confidence intervals to compare optimal performance in multi-State diagnostic tests with correlated Biomarkers
Beau Nunnally, Air Force Institute of Technology; Christine M Schubert, Air Force Institute of Technology; Katherine A Batterton, Air Force Institute of Technology
3:20 PM
|
|
Wednesday, 08/01/2018
|
A Stagewise Prognostic Control Predictive Approach (SPCPA) for Subgroup Identification and Its Application in a Phase II Study
Wanying Li, Gilead Sciences; Wangshu Zhang, Gilead Sciences; Lovely Goyal, Gilead Sciences; Yuanyuan Xiao, Gilead Sciences
|
Subgroup Selection in Adaptive Signature Designs of Confirmatory Clinical Trials
Zhiwei Zhang, University of California at Riverside
8:35 AM
|
Bayesian Latent Class Models for Identifying Biomarkers in Circadian Patterns
Sung Duk Kim, National Cancer Institute; Paul S Albert, National Cancer Institute
8:35 AM
|
A Stagewise Prognostic Control Predictive Approach (SPCPA) for Subgroup Identification and Its Application in a Phase II Study
Wanying Li, Gilead Sciences; Wangshu Zhang, Gilead Sciences; Lovely Goyal, Gilead Sciences; Yuanyuan Xiao, Gilead Sciences
8:35 AM
|
Joint Analysis of Multiple Highly Correlated Biomarkers and an Event Time via a Longitudinal Principal Component Approach
Gang Li, UCLA
8:55 AM
|
A Case Study of Adaptive Seamless Design with Subpopulation Selection in Oncology
Rui Qin, Janssen Pharmaceutical R&D
8:55 AM
|
Multiplicity for a Group Sequential Trial with Biomarker Subpopulations
Jing Zhao, Merck
9:20 AM
|
A Biomarker-Directed Phase 2 Oncology Umbrella Trial to Target Combination Therapy in NSCLC
Hua Ma, Merck; Robin Mogg, Merck Research Laboratories
9:35 AM
|
Time-To-Event Data with Time-Varying Biomarkers Measured Only at Study Entry, with Applications to Alzheimer's Disease
Catherine Lee, Kaiser Permanente Division of Research; Rebecca A. Betensky, Harvard School of Public Health
10:50 AM
|
Inference on Multiple AUCs Based on the Combination of Multiple Biomarkers
Shu-Hui Lin, National Taichung University of Science and Technology
2:20 PM
|
Add Time Dimension to the Prediction: a Multi-Stage, Sequential Prediction Model
Zheng Zhang, Brown University
3:35 PM
|
|
Thursday, 08/02/2018
|
Dynamic Prediction of Competing Risk Events using Landmark Sub-distribution Hazard Model with Multivariate Longitudinal Biomarkers
Cai Wu, Merck & Co.; Liang Li, UT MD Anderson Cancer Center; Ruosha Li, University of Texas School of Public Health
8:50 AM
|
Adjusting for Handling Effects in Microarray Data for Prognostic Biomarker Discovery and Survival Risk Prediction
Ai Ni, Memorial Sloan Kettering Cancer Center; Mengling Liu, New York University; Li-Xuan Qin, Memorial Sloan Kettering Cancer Center
9:05 AM
|
Evaluating Biomarkers for Prognostic Enrichment of Clinical Trials
Kathleen F. Kerr, University of Washington; Jeremy Roth, University of Washington; Kehao Zhu, Axio Research; Heather Thiessen-Philbrook, Yale University; Allison Meisner, Johns Hopkins University; Francis Perry Wilson, Yale University; Steven Coca, Icahn School of Medicine at Mount Sinai; Chirag Parikh, Yale University
10:35 AM
|
Using Surrogate Biomarker Information to Plan a Future Clinical Trial
Layla Parast, RAND; Tianxi Cai, Harvard T.H. Chan School of Public Health; Lu Tian, Stanford University School of Medicine
11:00 AM
|
Bias-Corrected Estimation of Treatment Effects in Biomarker-Based Adaptive Subgroup Analysis: New Approach Based on Randomized Tests with Smooth Rejection Function
Kiichiro Toyoizumi, Shionogi Inc.; Shigeyuki Matsui, Nagoya University
11:05 AM
|
Biomarker Guided Phase II Two-Stage Design for Targeted Therapy
Zheyu Wang, Johns Hopkins University; Fujun Wang, Medimmune; Chenguang Wang, Johns Hopkins University; Gary Rosner, Johns Hopkins University; Jianliang Zhang, Medimmune; Hao Wang, Johns Hopkins University; Li Shi, Medimmune
11:25 AM
|
Evaluating the Ability of a Biomarker to Improve the Diagnosis of Malaria Infection in Malaria 'Challenge' Trials
Holly Janes, Fred Hutchinson Cancer Research Center
11:50 AM
|
|
|
